Fmr Llc - Jan 8, 2025 Form 4 Insider Report for Sana Biotechnology, Inc. (SANA)

Role
Other*, 10%+ Owner
Signature
/s/ Stephanie J. Brown, Duly authorized under Powers of Attorney, by and on behalf of FMR LLC and its direct and indirect subsidiaries, and Abigail P. Johnson
Stock symbol
SANA
Transactions as of
Jan 8, 2025
Transactions value $
-$1,887,320
Form type
4
Date filed
1/10/2025, 01:32 PM
Previous filing
Sep 18, 2024
Next filing
Jan 30, 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SANA Common Stock Sale -$611K -100K -2.07% $6.11 4.73M Jan 8, 2025 F-Prime Capital Partners Life Sciences Fund VI LP F1
transaction SANA Common Stock Sale -$163K -25K -0.53% $6.50 4.71M Jan 8, 2025 F-Prime Capital Partners Life Sciences Fund VI LP F2
transaction SANA Common Stock Sale -$1.11M -165K -3.5% $6.71 4.54M Jan 8, 2025 F-Prime Capital Partners Life Sciences Fund VI LP F3
transaction SANA Common Stock Sale -$7.26K -1K -0.02% $7.26 4.54M Jan 8, 2025 F-Prime Capital Partners Life Sciences Fund VI LP
holding SANA Common Stock 61 Jan 8, 2025 FMR Capital, Inc.
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $6.05 to $6.24. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F2 The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $6.50 to $6.55. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F3 The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $6.20 to $6.98. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Remarks:

Remark 1: Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. The address of Abigail P. Johnson is c/o FMR LLC, 245 Summer Street, Boston, MA 02110. Remark 2: The filing of this statement shall not be deemed to be an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the undersigned are the beneficial owners of any securities reported herein. Remark 3: F-Prime Capital Partners Life Sciences Advisors Fund VI LP (FPCPLSA) is the general partner of F-Prime Capital Partners Life Sciences Fund VI LP. FPCPLSA is solely managed by Impresa Management LLC, the managing member of its general partner and its investment manager. Impresa Management LLC is owned, directly or indirectly, by various shareholders and employees of FMR LLC, including certain members of the Johnson family. FMR Capital, Inc. is a wholly owned subsidiary of FMR LLC.